Company registration number 10827280 (England and Wales)
GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 5
GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
BALANCE SHEET
AS AT
30 JUNE 2025
30 June 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
3
24,531
48,146
Cash at bank and in hand
308,770
360,066
333,301
408,212
Creditors: amounts falling due within one year
4
(24,051)
(17,099)
Net current assets
309,250
391,113
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
309,150
391,013
Total equity
309,250
391,113

For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 19 October 2025 and are signed on its behalf by:
Dr G A Ross
Director
Company registration number 10827280 (England and Wales)
GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2025
- 2 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 July 2023
100
403,194
403,294
Year ended 30 June 2024:
Profit and total comprehensive income
-
36,389
36,389
Dividends
-
(48,570)
(48,570)
Balance at 30 June 2024
100
391,013
391,113
Year ended 30 June 2025:
Loss and total comprehensive income
-
(33,293)
(33,293)
Dividends
-
(48,570)
(48,570)
Balance at 30 June 2025
100
309,150
309,250
GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 3 -
1
Accounting policies
Company information

Graham Ross Oncology Consulting Services Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 12 Digswell Road, Welwyn Garden City, Hertfordshire, AL8 7PA.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for medical consultancy services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

 

The company recognises turnover in the period in which the services are provided.

1.4
Financial instruments

Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

1.5
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -
1.6
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

 

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
2
2
3
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
11,820
44,494
Other debtors
12,711
3,652
24,531
48,146
4
Creditors: amounts falling due within one year
2025
2024
£
£
Taxation and social security
-
0
13,855
Other creditors
24,051
3,244
24,051
17,099
GRAHAM ROSS ONCOLOGY CONSULTING SERVICES LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 5 -
5
Related party transactions

At the balance sheet date, £16,756 (2024: £1,444) was due from the company to the directors. The loan is interest free and repayable upon demand.

2025-06-302024-07-01falsetruefalse21 October 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityDr G A RossMrs W J RossMrs W J Ross108272802024-07-012025-06-30108272802025-06-30108272802024-06-3010827280core:CurrentFinancialInstrumentscore:WithinOneYear2025-06-3010827280core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3010827280core:ShareCapital2025-06-3010827280core:ShareCapital2024-06-3010827280core:RetainedEarningsAccumulatedLosses2025-06-3010827280core:RetainedEarningsAccumulatedLosses2024-06-3010827280core:ShareCapital2023-06-3010827280core:RetainedEarningsAccumulatedLosses2023-06-3010827280bus:Director12024-07-012025-06-3010827280core:RetainedEarningsAccumulatedLosses2023-07-012024-06-30108272802023-07-012024-06-3010827280core:RetainedEarningsAccumulatedLosses2024-07-012025-06-3010827280core:CurrentFinancialInstruments2025-06-3010827280core:CurrentFinancialInstruments2024-06-3010827280core:WithinOneYear2025-06-3010827280core:WithinOneYear2024-06-3010827280bus:PrivateLimitedCompanyLtd2024-07-012025-06-3010827280bus:SmallCompaniesRegimeForAccounts2024-07-012025-06-3010827280bus:FRS1022024-07-012025-06-3010827280bus:AuditExemptWithAccountantsReport2024-07-012025-06-3010827280bus:Director22024-07-012025-06-3010827280bus:CompanySecretary12024-07-012025-06-3010827280bus:FullAccounts2024-07-012025-06-30xbrli:purexbrli:sharesiso4217:GBP